Table 3

Sensitivity analysis results

 NumberAge, mean (SD) cohortOpium users (8487) vs non-users (41 558)*NumberOpium users (8349) vs
non-users (41 320)†
NumberOpium users (4535) vs non-users (41 558)‡
The entire cohort 50 045 52.1 (9.02)
All respiratory mortality 331 60.8 (9.49) 3.13 (2.42–4.04) 278 2.99 (2.26–3.96) 279 3.44 (2.55–4.65)
Malignant respiratory mortality8559.6 (9.47)1.96 (1.18–3.25)651.83 (1.02–3.29)782.66 (1.53–4.62)
 Lung cancer7059.2 (9.02) 1.73 (0.99–3.03)511.61 (0.82–3.14)652.42 (1.32–4.46)
 Laryngeal cancer1561.5 (11.5) 3.46 (0.99–12.07)142.92 (0.81–10.51)134.16 (1.1–15.74)
Non-malignant respiratory mortality 246 61.2 (9.47) 3.71 (2.76–4.96) 213 3.47 (2.53–4.76) 201 3.89 (2.73–5.55)
 COPD9762.1 (8.77) 7.21 (4.46–11.65)787.03 (4.11–12.02)757.54 (4.33–13.14)
 Asthma3858.6 (9.05) 3.87 (1.85–8.11)353.51 (1.57–7.81)325.01 (2.11–11.86)
 Pneumonia6661.5 (10.4) 3.01 (1.67–5.37)602.92 (1.58–5.38)522.36 (1.08–5.14)
 Other4561.4 (9.8)1.09 (0.48–2.45)421.11 (0.47–2.57)421.31 (0.49–3.44)
  • *HRs are adjusted for age, sex, residential place, education, marital status, drinking alcohol and cumulative use of any type of tobacco (pack-years for cigarette and amount×duration of use for hookah and nass).

  • †Excluding 841 deaths occurred during the first 24 months after enrolment.

  • ‡Excluding 3952 subjects who used opium for <10 years.